Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03531957 · ClinicalTrials.gov registry record · Phase 2
Phase 2B Study to Evaluate ASN002 in Subjects With Moderate to Severe Atopic Dermatitis (RADIANT)
A Phase 2 study, sponsored by Asana BioSciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 244
- Enrollment target
NCT03531957 is a Phase 2 study that has completed, run by Asana BioSciences. The registered enrollment target is 244 participants.
The verdict
NCT03531957, a Phase 2 study, has completed, sponsored by Asana BioSciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 244 participants
- Enrollment target
Study Summary
This is a randomized double-blind/placebo study evaluate the efficacy of ASN002 in subjects with moderate to severe atopic dermatitis (AD).
Interventions
- DRUG Placebo Oral Tablet
- DRUG ASN002
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 244 participants |
| Start Date | 2018-07-05 |
| Est. Completion | 2019-08-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03531957
The ClinicalTrials.gov registry entry for NCT03531957 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 244 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Asana BioSciences, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Oral Tablet is the first listed.
NCT03531957 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03531957 about?
NCT03531957 is a clinical study titled "Phase 2B Study to Evaluate ASN002 in Subjects With Moderate to Severe Atopic Dermatitis (RADIANT)". This is a randomized double-blind/placebo study evaluate the efficacy of ASN002 in subjects with moderate to severe atopic dermatitis (AD).
What is the current status of trial NCT03531957?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 244 participants. The study started on 2018-07-05. Estimated completion is 2019-08-14.
What interventions are being tested in trial NCT03531957?
The interventions under investigation include: Placebo Oral Tablet (DRUG), ASN002 (DRUG).
Who is sponsoring clinical trial NCT03531957?
This trial is sponsored by Asana BioSciences, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.